GlassScriptPhysician profile
Gabriel Barnard
NPI 1093150963
$13,136.62
in general payments reported to CMS, 2019-2025
26 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,538 · 2020: $3,030 · 2021: $999 · 2022: $1,008 · 2023: $928 · 2024: $1,108 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,562.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $4,031.51 | 2019-2020 | |
| Boston Scientific Corporation | $2,969.67 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $1,468.94 | 2021-2025 | Intellis Adaptivestim |
| Abbott Laboratories | $1,249.92 | 2019-2023 | Eterna |
| Stimwave Technologies Incorporated | $612.94 | 2019-2021 | |
| Nevro Corp. | $540.54 | 2019-2024 | Senza |
| Nalu Medical, INC. | $536.24 | 2023-2024 | Nalu Neurostimulation System |
| Allergan, INC. | $334.64 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $163.53 | 2021-2023 | Xeomin |
| Stryker Corporation | $154.49 | 2019 | |
| Abbvie INC. | $153.08 | 2021-2025 | Ubrelvy |
| Depuy Synthes Sales INC. | $141.42 | 2019-2023 | Monovisc |
| Merz North America, INC. | $125.00 | 2020 | |
| Innovation Technologies INC | $115.87 | 2021 | |
| Spr Therapeutics, INC | $109.08 | 2022-2024 | Sprint Pns System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $87.28 | 2019 | |
| Biotissue Holdings INC. | $73.26 | 2024-2025 | |
| Bioventus LLC | $55.01 | 2022-2023 | L360 Thigh System |
| Forte Bio-Pharma LLC | $53.91 | 2020 | |
| Tersera Therapeutics LLC | $28.14 | 2024 | Prialt |
| Relievant Medsystems, INC. | $25.66 | 2023 | Intracept |
| Biotronik Nro, INC. | $24.17 | 2024 | Prospera |
| Averitas Pharma INC. | $22.06 | 2023 | Qutenza |
| Virtus Pharmaceuticals LLC | $21.32 | 2024 | Levorphanol Tartrate |
| Curonix LLC | $20.39 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Electronic Waveform Lab, INC. | $18.55 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Barnard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.